Reimbursement Review Reports


( Last Updated : April 2, 2015)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Abecma idecabtagene vicleucel Multiple myeloma Do not reimburse Active
Abilify Aripiprazole Schizophrenia Do not list Complete
Abilify Aripiprazole Depression, Major Depressive Disorder Do not list Complete
Abilify Aripiprazole Schizophrenia and related psychotic disorders List with clinical criteria and/or conditions Complete
Abilify Maintena Aripiprazole Schizophrenia List with criteria/condition Complete
Abraxane Nab-paclitaxel Metastatic Pancreatic Cancer Reimburse with clinical criteria and/or conditions Complete
Abstral Fentanyl citrate Pain, breakthrough cancer pain Do not list Complete
Aclasta Zoledronic acid Osteoporosis, postmenopausal women Do not list Complete
Aclasta Zoledronic acid Osteoporosis List with clinical criteria and/or conditions Complete
Actemra Tocilizumab Arthritis, juvenile idiopathic List with clinical criteria and/or conditions Complete